Data Analysis: The primary analysis will be by intent-to-treat and will compare the diagnostic yield (arrhythmia detection or exclusion) at the end of 15-days using data from 15-day monitoring in the intervention arm and the 48-hour holter monitoring followed by arrhythmia detection or exclusion when patients seek care based on their symptoms (not based on the 13-day event recordings by the MCT device). Secondary analysis will include a per-protocol analysis. The Cochran-Mantel-Haenszel test will be used for the primary outcome, controlling for the stratification factor (CSARS score). The effect of the intervention will be expressed as a risk difference with 95% confidence interval. Secondary analysis will include multivariable logistic regression to control for potential confounders or imbalances between patients in the study arms. Descriptive statistics for baseline characteristics, all outcomes, device performance including failure and patient centered measures (adherence, comfort and safety feeling). Additional analysis will include comparison of arrhythmias detected that did not require treatment between the groups. There will no interim analyses for efficacy performed, but the investigators will monitor trial safety as detailed in the Data Safety Monitoring Board section.